Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
One of these Gilead studies compares momelotinib head-to-head against Jakafi, another Jak inhibitor and the current standard of care in myelofibrosis marketed by Incyte (INCY) and Novartis (NVS) . The second study compares Gilead’s momelotinib against best alternative care in patients previously treated with Jakafi.
